Skip to main content

Advertisement

Fig. 7 | Breast Cancer Research

Fig. 7

From: Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

Fig. 7

Synergy between pertuzumab and lapatinib in vivo. a IHC staining for RTK expression as indicated in the HCI-012 PDX model. (Scale bar = 25 μm). b Proximity mediated ligation assays detected heterodimers between ERBB2 and other RTKs as indicated, shown in red. (Scale bar = 25 μm). c Tumour growth following treatment with either vehicle, pertuzumab (12 mg/kg loading dose, 6 mg/k6 maintenance dose, intraperitoneal injection, once weekly), lapatinib (50 mg/kg, oral gavage, 5 times a week) or the combination of pertuzumab and lapatinib (n = 6, mean ± SEM, *p < 0.05). d Growth rate for each treatment arm calculated from a linear regression analysis (n = 6, mean ± SEM, **p < 0.01). e IHC staining for Ki67 from day 14 tumours. Analysis was performed on three random fields of view from three tumours for each arm (n = 9, mean ± SD, **p < 0.01)

Back to article page